Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Surinabant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 12/20 | 1.00 |
| ▸ | CNR2 | P34972 | 8/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.69 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.69 |
| ▸ | MLNR | O43193 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.69 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.69 |
| ▸ | DRD1 | P21728 | 1/20 | 0.69 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.69 |
| ▸ | HRH2 | P25021 | 1/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.69 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.69 |
| ▸ | CCKAR | P32238 | 1/20 | 0.69 |
| ▸ | CCKBR | P32239 | 1/20 | 0.69 |
| ▸ | MC4R | P32245 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Surinabant SCHEMBL30953789 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL5160340 | 0.94 | CNR1 (0.90) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| Surinabant SCHEMBL4002662 | 0.94 | CNR1 (0.89) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL12053804 | 0.92 | CNR1 (0.85) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL10138900 | 0.92 | CNR1 (0.85) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL12053658 | 0.91 | CNR1 (0.84) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| Surinabant SCHEMBL4002413 | 0.91 | CNR1 (0.84) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL8226008 | 0.91 | CNR1 (0.84) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL6162630 | 0.91 | CNR1 (0.82) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL12053648 | 0.91 | CNR1 (0.82) | CNR1CNR2CYP2C9GPR55ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 440 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544366-B2 | Combination of endocannabinoid and mTOR inhibitors in the treatment of neuroendocrine neoplasms | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2026-02-10 | — | — | US | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250288565-A1 | COMBINATION OF ENDOCANNABINOID AND MTOR INHIBITORS IN THE TREATMENT OF NEUROENDOCRINE NEOPLASMS | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2025-09-18 | — | — | US | claimed |
| EP-4525836-A1 | COMBINATION OF ENDOCANNABINOID AND MTOR INHIBITORS IN THE TREATMENT OF NEUROENDOCRINE NEOPLASMS | Hadasit Medical Research Services&Development Ltd. (IL) | 2025-03-26 | — | — | EP | claimed |
| US-20240408059-A1 | METHOD OF TREATING ADDICTION | ANEBULO PHARMACEUTICALS, INC. | 2024-12-12 | — | — | US | claimed |
| WO-2024129891-A1 | METHODS FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE BY MODULATING OR INHIBITING CANNABINOID RECEPTOR 1 | JOYBOY THE IGWE L.L.C. (US) | 2024-06-20 | — | — | WO | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2023223323-A1 | COMBINATION OF ENDOCANNABINOID AND MTOR INHIBITORS IN THE TREATMENT OF NEUROENDOCRINE NEOPLASMS | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2023-11-23 | — | — | WO | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| EP-1583758-A1 | DERIVATIVE OF 5-(4-BROMOPHENYL)-1-(2,4-DICHLOROPHENLY)-4-ETHYL-N-(PIPERIDINE-1-YL)-1H-PYRAZOL-3-CARBOXAMIDE, THE PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-10-12 | — | — | EP | claimed |
| WO-2005046689-A2 | USE OF A PYRAZOLE DERIVATIVE FOR PREPARING MEDICAMENTS FOR THE PREVENTION AND THE TREATMENT OF DYSLIPIDEMIA AND ILLNESSES ASSOCIATED WITH DYSLIPIDEMIA AND/OR OBESITY | SANOFI-AVENTIS (FR) | 2005-05-26 | — | — | WO | claimed |
| WO-2004058744-A1 | DERIVATIVE OF 5-(4-BROMOPHENYL)-1-(2,4-DICHLOROPHENLY)-4-ETHYL-N-(PIPERIDINE-1-YL)-1H-PYRAZOL-3-CARBOXAMIDE, THE PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2004-07-15 | — | — | WO | claimed |
| US-20040039024-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2004-02-26 | — | — | US | claimed |
| US-6645985-B2 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them, and method of treating | SANOFI (FR) | 2003-11-11 | — | — | US | claimed |
| EP-1150961-B1 | PYRAZOLECARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI SYNTHELABO (FR) | 2003-10-22 | — | — | EP | claimed |
| US-20020188007-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 2002-12-12 | — | — | US | claimed |
| US-6432984-B1 | CANNABINOID RECEPTOR ANTAGONISTS; TREATMENT OF OBESITY, DRUG ADDICTION, ALCHOLISM, PSYCHOLOGICAL, AND EATING DISORDERS | SANOFI-SYNTHELABO (FR) | 2002-08-13 | — | — | US | claimed |
| EP-1150961-A1 | PYRAZOLECARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2001-11-07 | — | — | EP | claimed |
| WO-2000046209-A1 | PYRAZOLECARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2000-08-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408059-A1 | METHOD OF TREATING ADDICTION | CNR2, CNR1, OPRM1 | CNR1 2/4885CNR2 1/4885CYP2C9 508/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | CNR1 221/4885CNR2 204/4885CYP2C9 313/4885 |
| US-20040039024-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | CNR1, CNR2, P2RY1 | CNR1 1/4885CNR2 2/4885CYP2C9 283/4885 |
| US-12544366-B2 | Combination of endocannabinoid and mTOR inhibitors in the treatment of neuroendocrine neoplasms | RICTOR, MTOR, RPTOR | CNR1 4/4885CNR2 5/4885CYP2C9 3955/4885 |
| US-20020188007-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | CNR1, CNR2, P2RY1 | CNR1 1/4885CNR2 2/4885CYP2C9 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.